Recently, the FDA approved ivosidenib for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. In this interview, Amir Fathi, MD, Director of the Leukemia Program at Massachusetts General Hospital, one of the leaders of the AG120-C-001 trial (NCT02074839), on which approval was based, sat down to further discuss the trial and approval, as well as what this could mean for the future treatment landscape of MDS. &n...